Mukka Proteins reappoints board, KMPs for five-year terms

1 min read     Updated on 12 Aug 2026, 09:08 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Mukka Proteins Ltd reappointed three independent directors and three key managerial personnel for five-year terms starting in January 2027. The board approved the moves on August 12, 2026, following Nomination and Remuneration Committee recommendations. Shareholder approval at the 16th AGM is required.

powered bylight_fuzz_icon
48094671

*this image is generated using AI for illustrative purposes only.

Mukka Proteins board of directors approved the reappointment of three independent directors and three key managerial personnel for five-year terms during a meeting held on August 12, 2026. The appointments, which commence in January 2027, are subject to shareholder approval at the company’s 16th Annual General Meeting.

The board acted on recommendations from the Nomination and Remuneration Committee to secure leadership continuity across both oversight and executive functions. The reappointments cover the period from mid-January 2027 to mid-January 2032 for independent directors, and from late January 2027 to late January 2032 for key managerial personnel.

Independent Director Reappointments

Three non-executive independent directors were approved for their second consecutive five-year terms:

  • Mr. Karkala Shankar Balachandra Rao (DIN: 03589394)
  • Mr. Hamad Bava (DIN: 094423)
  • Mr. Narendra Surendra Kamath (DIN: 07255904)

These directors are not liable to retire by rotation. Their terms begin on January 15, 2027, and end on January 14, 2032.

Key Managerial Personnel Reappointments

Three whole-time directors and executives were also approved for five-year terms beginning January 20, 2027:

Name Role Retire by Rotation
Kalandan Mohammed Haris Managing Director and CEO No
Kalandan Mohammed Althaf Whole-Time Director and CFO Yes
Kalandan Mohammad Arif Whole-Time Director and COO Yes

Mr. Haris, who serves as managing director and chief executive officer, is not liable to retire by rotation. Mr. Althaf, the chief financial officer, and Mr. Arif, the chief operating officer, are liable to retire by rotation.

Governance Compliance

The disclosures comply with Regulation 30(6) read with Schedule III of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The board confirmed that none of the appointees are debarred from holding office by virtue of any SEBI order or other authority.

The meeting commenced at 3:30 pm and concluded at 4:15 pm. Mehaboobsab Mahmadgous Chalyal, company secretary and compliance officer, certified the disclosure.

Historical Stock Returns for Mukka Proteins

1 Day5 Days1 Month6 Months1 Year5 Years
+1.68%+5.36%+0.75%-1.63%-10.48%-42.77%

How might Mukka Proteins' strategy of securing five-year leadership terms influence investor confidence regarding corporate stability and long-term strategic execution?

What specific operational or financial targets has the reappointed CEO and CFO outlined for the 2027-2032 period to justify this extended leadership continuity?

Given that two of the three key managerial personnel are liable to retire by rotation, what succession plans or contingency measures are in place to mitigate potential governance disruptions?

Mukka Proteins shareholders approve ₹47 crore preferential warrant issue

3 min read     Updated on 08 Aug 2026, 05:12 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Mukka Proteins Limited shareholders approved a ₹47 crore preferential warrant issue via postal ballot on July 12, 2026. The 2 crore warrants priced at ₹23.50 each will convert into equity shares within 18 months. The resolution received strong support with 218 out of 252 voting members in favor, representing over 99.96% of votes cast.

powered bylight_fuzz_icon
47734913

*this image is generated using AI for illustrative purposes only.

Shareholders of Mukka Proteins have approved a special resolution to issue warrants convertible into equity shares on a preferential basis, enabling the company to raise capital of up to ₹47 crore. The approval, secured through a postal ballot concluded on July 12, 2026, allows the Board of Directors to allot up to 2 crore warrants at an issue price of ₹23.50 per warrant. This financing structure provides flexibility for future equity conversion while securing immediate funding commitments from non-promoter investors.

The postal ballot process was conducted via remote e-voting from June 13, 2026, to July 12, 2026, with results declared on July 14, 2026. The proposal was initially notified on June 12, 2026, followed by a corrigendum issued on July 6, 2026, after exchanges sought clarifications regarding the preferential issue. Central Depository Services (India) Limited (CDSL) facilitated the e-voting platform, while Chethan Nayak & Associates served as the scrutinizer for the process.

Issue Structure and Terms

The warrant issuance follows specific regulatory frameworks under the Companies Act, 2013, and SEBI ICDR Regulations. Key terms of the issue include:

Parameter Details
Total Issue Size Up to ₹47 crore
Number of Warrants Up to 2 crore
Issue Price per Warrant ₹23.50
Conversion Right 1 Equity Share per Warrant
Exercise Period 18 months from allotment
Subscription Payment 25% upfront, 75% upon exercise
Lock-in Period As per SEBI ICDR Regulations

Warrant holders must pay 25% of the issue price (₹5.875 per warrant) at subscription, which will be adjusted against the final equity share price. The remaining 75% is payable when exercising the warrant. If warrants remain unexercised within 18 months, they lapse and the paid amount is forfeited by the company. The equity shares arising from conversion will rank pari-passu with existing equity shares in all respects, including dividend rights.

Allotment Details

The warrants are being allotted to 15 non-promoter entities and individuals. The allocation reflects diverse investor participation, including individual investors, Hindu Undivided Families (HUFs), and institutional players like Multiplex Capital Limited.

| Proposed Allottee | Category | Warrants Allotted | |---:|:---| | Mr. Irfan Chapra | Non-Promoter | 21,75,000 | | Ms. Reshma Chapra | Non-Promoter | 21,75,000 | | Mr. Vishal Maniar | Non-Promoter | 25,00,000 | | Ms. Payal Maniar | Non-Promoter | 12,00,000 | | Mr. Jasbir Singh Batra | Non-Promoter | 5,00,000 | | Mr. Ranjit Singh Batra | Non-Promoter | 5,00,000 | | Mr. Gurminder Kaur | Non-Promoter | 4,00,000 | | Jasbir Singh And Sons HUF | Non-Promoter | 4,00,000 | | Mr. Sarabdeep Kaur Darshan Singh | Non-Promoter | 4,00,000 | | Ranjit Singh and Sons HUF | Non-Promoter | 4,00,000 | | Multiplex Capital Limited | Non-Promoter | 3,50,000 | | Mr. Hiren Hiralal Shiyal | Non-Promoter | 22,50,000 | | Mr. B A Abdul Nasir | Non-Promoter | 22,50,000 | | Mr. Soofikhan Kalandar Asif | Non-Promoter | 22,50,000 | | Mr. B H Rizwan | Non-Promoter | 22,50,000 |

The floor price for the warrants was determined based on the relevant date of June 12, 2026, as per Regulation 161 of SEBI ICDR Regulations. Allotment must be completed within 15 days of resolution passage, subject to regulatory approvals.

Voting Outcome

The postal ballot received substantial participation from shareholders. Out of 1,30,984 shareholders on the cut-off date of June 10, 2026, 252 members cast votes representing 22,02,62,108 total votes. The resolution passed with overwhelming support:

| Voting Category | Members Voted | Votes Cast | |---:|:---| | Total Votes | 252 | 22,02,62,108 | | Votes in Favour | 218 | 22,01,79,675 | | Votes Against | 34 | 82,433 | | Invalid Votes | - | - |

No shareholder requested modification of votes already cast before the corrigendum issuance. The Chairman, Karkala Shankar Balachandra Rao, declared the resolution passed with requisite majority on July 12, 2026, and results were communicated to stock exchanges and uploaded on the company website on July 14, 2026.

Historical Stock Returns for Mukka Proteins

1 Day5 Days1 Month6 Months1 Year5 Years
+1.68%+5.36%+0.75%-1.63%-10.48%-42.77%

How will the potential dilution of up to 2 crore equity shares impact Mukka Proteins' earnings per share (EPS) and existing promoter ownership stakes upon full warrant exercise?

What specific strategic initiatives or capital expenditures does Mukka Proteins plan to fund with the ₹47 crore raised through this preferential warrant issuance?

Given the 18-month exercise window, what market conditions or company performance metrics would likely incentivize investors to convert their warrants into equity before expiry?

More News on Mukka Proteins

1 Year Returns:-10.48%